Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur D. L. COURY |
Documents disponibles écrits par cet auteur (3)
Faire une suggestion Affiner la recherche
Associations of quality of life with health-related characteristics among children with autism / Karen A. KUHLTHAU in Autism, 22-7 (October 2018)
[article]
Titre : Associations of quality of life with health-related characteristics among children with autism Type de document : Texte imprimé et/ou numérique Auteurs : Karen A. KUHLTHAU, Auteur ; E. MCDONNELL, Auteur ; D. L. COURY, Auteur ; N. PAYAKACHAT, Auteur ; E. MACKLIN, Auteur Article en page(s) : p.804-813 Langues : Anglais (eng) Mots-clés : Pediatric Quality of Life Inventory 4.0 autism health health-related quality of life longitudinal pediatric Index. décimale : PER Périodiques Résumé : We examine whether behavioral, mental health, and physical health characteristics of children with autism are associated with baseline and change in health-related quality of life. We measured health-related quality of life with the Pediatric Quality of Life Inventory 4.0 total scores from children enrolled in the Autism Treatment Network. We used linear mixed model regressions with random slopes. Predictors of lower health-related quality of life at baseline included demographic and insurance characteristics, diagnosis, higher Child Behavior Checklist internalizing and externalizing scores, sleep problems by Children's Sleep Habits Questionnaire, seizures, gastrointestinal problems, and mental health problems. Several characteristics had different associations over time. This study demonstrates that in addition to behavioral and autism-related characteristics, physical and mental health conditions are associated with health-related quality of life in children with autism. En ligne : http://dx.doi.org/10.1177/1362361317704420 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=369
in Autism > 22-7 (October 2018) . - p.804-813[article] Associations of quality of life with health-related characteristics among children with autism [Texte imprimé et/ou numérique] / Karen A. KUHLTHAU, Auteur ; E. MCDONNELL, Auteur ; D. L. COURY, Auteur ; N. PAYAKACHAT, Auteur ; E. MACKLIN, Auteur . - p.804-813.
Langues : Anglais (eng)
in Autism > 22-7 (October 2018) . - p.804-813
Mots-clés : Pediatric Quality of Life Inventory 4.0 autism health health-related quality of life longitudinal pediatric Index. décimale : PER Périodiques Résumé : We examine whether behavioral, mental health, and physical health characteristics of children with autism are associated with baseline and change in health-related quality of life. We measured health-related quality of life with the Pediatric Quality of Life Inventory 4.0 total scores from children enrolled in the Autism Treatment Network. We used linear mixed model regressions with random slopes. Predictors of lower health-related quality of life at baseline included demographic and insurance characteristics, diagnosis, higher Child Behavior Checklist internalizing and externalizing scores, sleep problems by Children's Sleep Habits Questionnaire, seizures, gastrointestinal problems, and mental health problems. Several characteristics had different associations over time. This study demonstrates that in addition to behavioral and autism-related characteristics, physical and mental health conditions are associated with health-related quality of life in children with autism. En ligne : http://dx.doi.org/10.1177/1362361317704420 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=369 Effect of Omega-3 and -6 Supplementation on Language in Preterm Toddlers Exhibiting Autism Spectrum Disorder Symptoms / K. W. SHEPPARD in Journal of Autism and Developmental Disorders, 47-11 (November 2017)
[article]
Titre : Effect of Omega-3 and -6 Supplementation on Language in Preterm Toddlers Exhibiting Autism Spectrum Disorder Symptoms Type de document : Texte imprimé et/ou numérique Auteurs : K. W. SHEPPARD, Auteur ; K. M. BOONE, Auteur ; B. GRACIOUS, Auteur ; M. A. KLEBANOFF, Auteur ; L. K. ROGERS, Auteur ; J. RAUSCH, Auteur ; C. BARTLETT, Auteur ; D. L. COURY, Auteur ; S. A. KEIM, Auteur Article en page(s) : p.3358-3369 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Children born preterm Language development MacArthur Bates communicative development inventory Omega-3 fatty acids Omega-6 fatty acids Index. décimale : PER Périodiques Résumé : Delayed language development may be an early indicator of autism spectrum disorder (ASD). Early intervention is critical for children with ASD, and the present study presents pilot data on a clinical trial of omega-3 and -6 fatty acid supplementation and language development, a secondary trial outcome, in children at risk for ASD. We randomized 31 children to receive an omega-3 and -6 supplement or a placebo for 3 months, and measured their language abilities at baseline and after supplementation. Gesture use, but not word production, increased for children in the treatment group more than children in the placebo group. These results suggest possible effectiveness of omega-3 and -6 supplementation for language development in children at risk for ASD. En ligne : http://dx.doi.org/10.1007/s10803-017-3249-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=324
in Journal of Autism and Developmental Disorders > 47-11 (November 2017) . - p.3358-3369[article] Effect of Omega-3 and -6 Supplementation on Language in Preterm Toddlers Exhibiting Autism Spectrum Disorder Symptoms [Texte imprimé et/ou numérique] / K. W. SHEPPARD, Auteur ; K. M. BOONE, Auteur ; B. GRACIOUS, Auteur ; M. A. KLEBANOFF, Auteur ; L. K. ROGERS, Auteur ; J. RAUSCH, Auteur ; C. BARTLETT, Auteur ; D. L. COURY, Auteur ; S. A. KEIM, Auteur . - p.3358-3369.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 47-11 (November 2017) . - p.3358-3369
Mots-clés : Autism spectrum disorder Children born preterm Language development MacArthur Bates communicative development inventory Omega-3 fatty acids Omega-6 fatty acids Index. décimale : PER Périodiques Résumé : Delayed language development may be an early indicator of autism spectrum disorder (ASD). Early intervention is critical for children with ASD, and the present study presents pilot data on a clinical trial of omega-3 and -6 fatty acid supplementation and language development, a secondary trial outcome, in children at risk for ASD. We randomized 31 children to receive an omega-3 and -6 supplement or a placebo for 3 months, and measured their language abilities at baseline and after supplementation. Gesture use, but not word production, increased for children in the treatment group more than children in the placebo group. These results suggest possible effectiveness of omega-3 and -6 supplementation for language development in children at risk for ASD. En ligne : http://dx.doi.org/10.1007/s10803-017-3249-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=324 Evidence-based use of scalable biomarkers to increase diagnostic efficiency and decrease the lifetime costs of autism / T. W. FRAZIER in Autism Research, 14-6 (June 2021)
[article]
Titre : Evidence-based use of scalable biomarkers to increase diagnostic efficiency and decrease the lifetime costs of autism Type de document : Texte imprimé et/ou numérique Auteurs : T. W. FRAZIER, Auteur ; D. L. COURY, Auteur ; K. SOHL, Auteur ; Kayla E. WAGNER, Auteur ; R. UHLIG, Auteur ; S. D. HICKS, Auteur ; F. A. MIDDLETON, Auteur Article en page(s) : p.1271-1283 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/diagnosis Autistic Disorder Biomarkers Child Early Diagnosis Humans Mass Screening United States autism spectrum disorder biomarkers cost analysis early diagnosis evidence-based assessment developer of the eye tracking test that was used in the EBM analysis. Thomas W. Frazier has received federal funding or research support from, acted as a consultant to, received travel support from, and/or received a speaker's honorarium from Quadrant Biosciences, Impel NeuroPharma, F. Hoffmann?La Roche AG Pharmaceuticals, the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol?Myers Squibb, Roche Pharma, National Institutes of Health, and the Brain and Behavior Research Foundation and has an investor stake in AutismEYES LLC. Steven D. Hicks and Frank A. Middleton are co?developers of the saliva RNA based autism test that is used in the EBM analysis, and members of the Clinical and Scientific Advisory Boards of Quadrant Biosciences. Kristin Sohl is director of ECHO Autism and both Kristin Sohl and Daniel L. Coury are a member of the Clinical Advisory Board of Quadrant Biosciences. Daniel L. Coury has received federal funding or research support from National Institutes of Health, GW Biosciences, Neurim, Stemina Biosciences, and Stalicla SA and acted as a consultant to BioRosa, Cognoa, GW Biosciences, and Stalicla SA. Kayla E. Wagner and Richard Uhlig are employees of Quadrant Biosciences. Quadrant Biosciences holds patent rights and exclusive sales rights for the Clarifi ASD saliva test. Index. décimale : PER Périodiques Résumé : Challenges associated with the current screening and diagnostic process for autism spectrum disorder (ASD) in the US cause a significant delay in the initiation of evidence-based interventions at an early age when treatments are most effective. The present study shows how implementing a second-order diagnostic measure to high risk cases initially flagged positive from screening tools can further inform clinical judgment and substantially improve early identification. We use two example measures for the purposes of this demonstration; a saliva test and eye-tracking technology, both scalable and easy-to-implement biomarkers recently introduced in ASD research. Results of the current cost-savings analysis indicate that lifetime societal cost savings in special education, medical and residential care are estimated to be nearly $580,000 per ASD child, with annual cost savings in education exceeding $13.3 billion, and annual cost savings in medical and residential care exceeding $23.8 billion (of these, nearly $11.2 billion are attributable to Medicaid). These savings total more than $37 billion/year in societal savings in the US. Initiating appropriate interventions faster and reducing the number of unnecessary diagnostic evaluations can decrease the lifetime costs of ASD to society. We demonstrate the value of implementing a scalable highly accurate diagnostic in terms of cost savings to the US. LAY SUMMARY: This paper demonstrates how biomarkers with high accuracy for detecting autism spectrum disorder (ASD) could be used to increase the efficiency of early diagnosis. Results also show that, if more children with ASD are identified early and referred for early intervention services, the system would realize substantial costs savings across the lifespan. En ligne : http://dx.doi.org/10.1002/aur.2498 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449
in Autism Research > 14-6 (June 2021) . - p.1271-1283[article] Evidence-based use of scalable biomarkers to increase diagnostic efficiency and decrease the lifetime costs of autism [Texte imprimé et/ou numérique] / T. W. FRAZIER, Auteur ; D. L. COURY, Auteur ; K. SOHL, Auteur ; Kayla E. WAGNER, Auteur ; R. UHLIG, Auteur ; S. D. HICKS, Auteur ; F. A. MIDDLETON, Auteur . - p.1271-1283.
Langues : Anglais (eng)
in Autism Research > 14-6 (June 2021) . - p.1271-1283
Mots-clés : Autism Spectrum Disorder/diagnosis Autistic Disorder Biomarkers Child Early Diagnosis Humans Mass Screening United States autism spectrum disorder biomarkers cost analysis early diagnosis evidence-based assessment developer of the eye tracking test that was used in the EBM analysis. Thomas W. Frazier has received federal funding or research support from, acted as a consultant to, received travel support from, and/or received a speaker's honorarium from Quadrant Biosciences, Impel NeuroPharma, F. Hoffmann?La Roche AG Pharmaceuticals, the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol?Myers Squibb, Roche Pharma, National Institutes of Health, and the Brain and Behavior Research Foundation and has an investor stake in AutismEYES LLC. Steven D. Hicks and Frank A. Middleton are co?developers of the saliva RNA based autism test that is used in the EBM analysis, and members of the Clinical and Scientific Advisory Boards of Quadrant Biosciences. Kristin Sohl is director of ECHO Autism and both Kristin Sohl and Daniel L. Coury are a member of the Clinical Advisory Board of Quadrant Biosciences. Daniel L. Coury has received federal funding or research support from National Institutes of Health, GW Biosciences, Neurim, Stemina Biosciences, and Stalicla SA and acted as a consultant to BioRosa, Cognoa, GW Biosciences, and Stalicla SA. Kayla E. Wagner and Richard Uhlig are employees of Quadrant Biosciences. Quadrant Biosciences holds patent rights and exclusive sales rights for the Clarifi ASD saliva test. Index. décimale : PER Périodiques Résumé : Challenges associated with the current screening and diagnostic process for autism spectrum disorder (ASD) in the US cause a significant delay in the initiation of evidence-based interventions at an early age when treatments are most effective. The present study shows how implementing a second-order diagnostic measure to high risk cases initially flagged positive from screening tools can further inform clinical judgment and substantially improve early identification. We use two example measures for the purposes of this demonstration; a saliva test and eye-tracking technology, both scalable and easy-to-implement biomarkers recently introduced in ASD research. Results of the current cost-savings analysis indicate that lifetime societal cost savings in special education, medical and residential care are estimated to be nearly $580,000 per ASD child, with annual cost savings in education exceeding $13.3 billion, and annual cost savings in medical and residential care exceeding $23.8 billion (of these, nearly $11.2 billion are attributable to Medicaid). These savings total more than $37 billion/year in societal savings in the US. Initiating appropriate interventions faster and reducing the number of unnecessary diagnostic evaluations can decrease the lifetime costs of ASD to society. We demonstrate the value of implementing a scalable highly accurate diagnostic in terms of cost savings to the US. LAY SUMMARY: This paper demonstrates how biomarkers with high accuracy for detecting autism spectrum disorder (ASD) could be used to increase the efficiency of early diagnosis. Results also show that, if more children with ASD are identified early and referred for early intervention services, the system would realize substantial costs savings across the lifespan. En ligne : http://dx.doi.org/10.1002/aur.2498 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449